KPV: The α-MSH-Derived Anti-Inflammatory Tripeptide in Research

# KPV : The α-MSH-Derived Anti-Inflammatory Tripeptide in Research

Among the growing library of bioactive peptides under laboratory investigation, KPV (Lys-Pro-Val) occupies a unique position (PMID: 34547895). This tripeptide—just three amino acids long—represents the minimum effective signaling sequence of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid neuropeptide with deep evolutionary roots in immunomodulation. Despite its remarkably small size (molecular weight ~342 Da), KPV retains much of the anti-inflammatory potency of the full-length α-MSH molecule, making it one of the most studied minimal bioactive peptide fragments in inflammation research.

For dosing, reconstitution, and protocol details, see our KPV (Alpha-MSH Tripeptide) Dosage Protocol Guide: Reconstitution, Research Dosing & Anti-Inflammatory Research (2026).

This guide examines KPV's structure, mechanism of action, and the published research that has made it a subject of interest across immunology, gastroenterology, dermatology, and drug delivery science—all within the context of research use only (

References

• •PMID: 34547895
• •PMID: 29953505
• •PMID: 10816654

RUO) investigation.

---

Origin and Structure of KPV

From α-MSH to a Minimal Signaling Fragment

α-MSH (sequence: Ac-SYSMEHFRWGKPV-NH₂) is a tridecapeptide processed from proopiomelanocortin (POMC) in the pituitary gland and various peripheral tissues. It was historically studied for its role in melanogenesis—stimulating pigment production in melanocytes—but over decades of research, its immunomodulatory properties emerged as arguably more significant.

The critical finding that launched KPV as an independent research compound was the demonstration that the C-terminal tripeptide sequence (positions 11-13), Lys-Pro-Val, retains the anti-inflammatory activity of the full parent molecule (Luger et al., 2007). This was unexpected because the classical melanocortin pharmacophore—the His-Phe-Arg-Trp core (positions 6-9)—was thought to be essential for receptor binding and bioactivity.

Structural Properties

The lysine residue provides a positive charge at physiological pH, the proline introduces a rigid kink in the backbone, and the valine contributes hydrophobicity. This compact structure gives KPV favorable physicochemical properties for research: high aqueous solubility, stability relative to larger peptides, and the ability to cross biological barriers that exclude larger molecules.

---

Mechanism of Action

NF-κB Pathway Inhibition

The most extensively characterized mechanism of KPV is its ability to inhibit the nuclear factor kappa-B (NF-κB) signaling cascade. NF-κB is a master transcription factor that orchestrates inflammatory gene expression—controlling the production of cytokines (TNF-α, IL-1β, IL-6, IL-8), adhesion molecules, and inflammatory enzymes like iNOS and COX-2.

In a landmark 2008 study published in Gastroenterology, Dalmasso et al. demonstrated that nanomolar concentrations of KPV inhibit NF-κB activation and MAP kinase inflammatory signaling pathways, reducing pro-inflammatory cytokine secretion in both immune cells and intestinal epithelial cells (Dalmasso et al., 2008). This is particularly notable because nanomolar potency from a tripeptide is unusual—most peptide anti-inflammatory agents require micromolar or higher concentrations.

The mechanism appears to involve inhibition of IκBα phosphorylation and degradation, thereby preventing NF-κB p65 subunit translocation to the nucleus. Without nuclear entry, NF-κB cannot bind DNA promoter regions and activate transcription of inflammatory genes.

PepT1 Transporter-Mediated Uptake

A critical discovery in understanding KPV's mechanism was the identification of PepT1 (SLC15A1) as its cellular uptake transporter. PepT1 is a proton-coupled oligopeptide transporter expressed on intestinal epithelial cells and, importantly, on immune cells involved in inflammatory responses.

Dalmasso et al. showed that KPV's inhibition of NF-κB is dependent on PepT1-mediated intracellular uptake (Dalmasso et al., 2008). When PepT1 expression was knocked down or cells lacking PepT1 were used, KPV's anti-inflammatory effects were abolished. This suggests KPV acts intracellularly rather than through classical cell-surface receptor signaling—a mechanism distinct from how the full-length α-MSH molecule signals through melanocortin receptors (MCRs).

This finding has significant implications for research: PepT1 is upregulated during intestinal inflammation, meaning inflamed tissue may actually concentrate KPV more efficiently than healthy tissue—a form of natural targeting.

Melanocortin Receptor-Independent Pathways

While full-length α-MSH signals primarily through melanocortin receptors (MC1R through MC5R), KPV's mechanism appears to be largely independent of classical MCR binding. The His-Phe-Arg-Trp pharmacophore required for high-affinity MCR binding is absent from the KPV sequence.

However, research by Brzoska et al. (2012) in human bronchial epithelial cells demonstrated that KPV can still influence inflammatory signaling in the context of MC3R expression, suggesting some residual receptor interaction may occur in certain cell types, potentially at lower affinity (Brzoska et al., 2012). The relative contributions of PepT1-mediated intracellular action versus surface receptor signaling likely vary by tissue context—an area of ongoing investigation.

---

Research Applications

Intestinal Inflammation Models

KPV has been most extensively studied in the context of intestinal inflammation, where the combination of PepT1-mediated uptake and NF-κB inhibition creates a compelling mechanistic rationale.

#### DSS and TNBS Colitis Models

Kannengiesser et al. (2008) investigated KPV in two established murine models of intestinal inflammation: dextran sodium sulfate (DSS)-induced colitis and trinitrobenzene sulfonic acid (TNBS)-induced colitis. The study found that KPV demonstrated anti-inflammatory potential in both models, reducing inflammatory markers and tissue damage scores (Kannengiesser et al., 2008).

The Dalmasso et al. study further confirmed that orally administered KPV significantly decreased inflammation in DSS- and TNBS-induced colitis models, with effects comparable to or exceeding those of the full-length α-MSH molecule (Dalmasso et al., 2008). The oral efficacy is particularly noteworthy for a peptide—most peptides are degraded in the gastrointestinal tract before reaching their target.

Nanoparticle Delivery Systems

KPV's small size and defined mechanism have made it a model compound for advanced drug delivery research, particularly nanoparticle-based systems targeting the gastrointestinal tract.

#### Polysaccharide Hydrogel Nanoparticles

Laroui et al. (2010) developed KPV-loaded nanoparticles embedded in a polysaccharide hydrogel designed for colon-targeted delivery. The study demonstrated that nanoparticle-encapsulated KPV could be delivered at a concentration 12,000-fold lower than free KPV while maintaining equivalent anti-inflammatory efficacy in a colitis model (Laroui et al., 2010). This dramatic dose reduction has significant implications for the efficiency and feasibility of peptide-based research interventions.

#### Hyaluronic Acid-Functionalized Nanoparticles

Xiao et al. (2017) advanced this concept with hyaluronic acid (HA)-functionalized nanoparticles encapsulating KPV, loaded into a hydrogel for oral delivery. The HA-KPV-NP system was designed to exploit CD44 receptor overexpression on inflamed colonic tissue, providing dual targeting: colon-specific release from the hydrogel, plus active cellular targeting via HA-CD44 interaction (Xiao et al., 2017; PMC5498804).

#### ROS-Responsive Conjugates

More recent work (2024) in Science Advances described an inflammation-triggered self-immolative conjugate approach, where KPV was linked to a reactive oxygen species (ROS)-responsive carrier. In colitis models, the KPV-based conjugate (proKPV) achieved 3.8-fold greater colonic accumulation than free KPV, with enhanced efficacy even at a 20-fold lower concentration. This represents the cutting edge of targeted peptide delivery research.

Dermatological Research

The skin is one of the primary sites of α-MSH expression and melanocortin receptor activity, making KPV a natural candidate for dermatological inflammation research.

#### Contact Dermatitis Models

Studies have demonstrated that KPV applied either intravenously or topically was able to suppress contact dermatitis reactions and induce hapten-specific tolerance, mirroring the effects of full-length α-MSH (Luger et al., 2007). The ability to induce tolerance—not merely suppress acute inflammation—suggests KPV may influence adaptive immune responses in addition to innate inflammatory pathways.

#### Transdermal Delivery Research

KPV's small molecular weight (~342 Da) makes it amenable to transdermal delivery approaches. Research has explored iontophoretic delivery of KPV across microporated skin, demonstrating feasible transdermal transport—a research avenue with implications for topical anti-inflammatory compound development.

Ocular Research

Catania et al. (2006) investigated KPV's effects on corneal epithelial wound models and found that KPV facilitated corneal epithelial wound closure, with a mechanism potentially involving nitric oxide (NO) disposition in corneal tissue (Catania et al., 2006). In the study, corneal samples exposed to KPV exhibited complete re-epithelialization within 60 hours, compared to control groups where healing was incomplete in the same timeframe. This suggests KPV may have reparative properties beyond pure anti-inflammatory activity.

Neuroinflammation Research

The brain expresses both α-MSH and melanocortin receptors, and early research established that α-MSH peptides—including the KPV fragment—modulate neuroinflammatory responses.

Ichiyama et al. (2000) described how α-MSH and its KPV fragment modulate inflammation through three general pathways: direct actions on peripheral immune cells, actions on inflammatory cells within the brain to modulate local reactions, and descending neural anti-inflammatory pathways that control peripheral tissue inflammation (Ichiyama et al., 2000).

Galimberti et al. (1999) demonstrated that α-MSH peptides inhibit production of nitric oxide and TNF-α by microglial cells activated with beta-amyloid and interferon-gamma (Galimberti et al., 1999). This finding positioned melanocortin peptides as potential tools for studying the inflammatory component of neurodegenerative processes, particularly amyloid-driven microglial activation.

Antimicrobial Properties

Beyond its anti-inflammatory profile, KPV demonstrates direct antimicrobial activity—a dual functionality shared with the parent α-MSH molecule and consistent with the broader category of host defense peptides.

Cutuli et al. (2000) demonstrated that α-MSH and its C-terminal fragment KPV exhibit antimicrobial influences against Staphylococcus aureus and Candida albicans (Cutuli et al., 2000). Catania et al. subsequently characterized a dimeric derivative, [Ac-CKPV]₂, which showed enhanced candidacidal activity and was structurally characterized by NMR (Catania et al., 2005).

The dual anti-inflammatory and antimicrobial properties of KPV align with the evolutionary role of α-MSH in barrier organ defense. The peptide's presence in skin and gut—organs constantly exposed to microbial challenges—suggests a conserved role in managing the balance between immune defense and inflammatory damage.

---

KPV vs. Full-Length α-MSH: Comparative Considerations

Understanding when to use KPV versus full-length α-MSH in research protocols requires consideration of several factors:

Advantages of KPV in Research Settings

• •Simplified synthesis: Three amino acids versus thirteen, reducing synthesis complexity and cost
• •Higher stability: Shorter peptides generally resist enzymatic degradation better
• •Oral bioavailability: KPV's small size and PepT1 transport mechanism enable oral activity in research models
• •Reduced off-target effects: Absence of the melanocortin pharmacophore means minimal melanogenic stimulation
• •Defined mechanism: PepT1-mediated uptake provides a clear, testable mechanistic framework

Limitations Relative to α-MSH

• •Reduced receptor affinity: KPV lacks the MCR binding domain, limiting receptor-mediated signaling studies
• •Narrower signaling scope: Full-length α-MSH activates multiple MCR subtypes with downstream effects KPV may not replicate
• •Context-dependent potency: In systems where MCR signaling is the primary anti-inflammatory pathway, KPV may be less effective

---

Research Handling and Stability

Reconstitution and Storage

KPV is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer systems. Due to its high aqueous solubility (driven by the charged lysine residue), reconstitution is straightforward at standard research concentrations.

For storage guidance applicable to small peptides, researchers can consult the Peptide Storage Best Practices guide, and for reconstitution protocols, the How to Reconstitute Peptides step-by-step guide provides general applicable guidance.

Stability Considerations

KPV's tripeptide structure confers relative stability compared to larger peptides, but standard precautions apply:

• •Store lyophilized: Lyophilized KPV at -20°C for long-term storage
• •Minimize freeze-thaw: Aliquot reconstituted solutions to avoid repeated freeze-thaw cycles
• •pH sensitivity: Maintain pH between 5.0 and 7.5 for optimal stability
• •Avoid oxidation: While KPV lacks methionine or cysteine residues susceptible to oxidation, general protective measures (argon overlay, amber vials) are best practice

For deeper context on peptide degradation mechanisms, the Peptide Degradation Pathways article covers chemical stability principles applicable to compounds of this class.

Purity Verification

Researchers should verify KPV purity using HPLC and confirm molecular identity via mass spectrometry. The expected [M+H]⁺ ion for KPV is approximately 343.4 m/z. For a comprehensive overview of analytical methods, see the Peptide Purity Testing Methods guide, and for interpreting supplier documentation, consult the COA Interpretation Guide.

---

Related Compounds and Research Context

KPV exists within a broader landscape of melanocortin-derived peptides and related anti-inflammatory compounds:

• •BPC-157: Another small peptide with anti-inflammatory research applications, though with a distinct mechanism centered on growth factor modulation rather than NF-κB inhibition
• •LL-37: A human cathelicidin antimicrobial peptide that shares KPV's dual anti-inflammatory/antimicrobial profile but through different receptor and signaling pathways
• •Thymosin Alpha 1: An immunomodulatory peptide with complementary mechanisms in immune regulation research
• •GHK-Cu: A tripeptide-copper complex with its own NF-κB modulatory properties in tissue regeneration research contexts
• •K(D)PT: A KPV derivative corresponding to amino acids 193-195 of IL-1β, emerging as another tripeptide with anti-inflammatory properties—currently less studied than KPV but representing an active area of investigation

---

Current Research Directions

Advanced Delivery Platforms

The most active area of KPV research is in targeted delivery systems. The peptide's defined size, mechanism, and GI tract relevance make it an ideal candidate for nanoparticle, hydrogel, and conjugate delivery platforms. Research groups continue to develop increasingly sophisticated approaches to maximize tissue-specific accumulation while minimizing systemic exposure.

Combination Approaches

Recent studies have explored co-assembly of KPV with immunosuppressant compounds in nanoparticle platforms, investigating whether dual-mechanism approaches can achieve synergistic effects in inflammation models (Frontiers in Pharmacology, 2024). This combinatorial approach reflects a broader trend in peptide research toward multi-target intervention strategies.

Microbiome Interface

Given KPV's antimicrobial properties and its activity at the intestinal epithelial barrier, emerging research is examining its interactions with the gut microbiome—how KPV's antimicrobial selectivity might influence microbial community composition, and conversely, how microbiome-derived signals might modulate KPV's anti-inflammatory effects.

---

Summary

KPV (Lys-Pro-Val) represents a compelling case study in minimal bioactive peptide pharmacology. From a 13-amino-acid parent molecule, the C-terminal three residues retain potent anti-inflammatory activity through a distinct PepT1-mediated, NF-κB-inhibiting mechanism. Its favorable physicochemical properties—small size, aqueous solubility, relative stability, and oral activity in research models—have established it as both a standalone research tool and a model compound for drug delivery innovation.

The research literature spanning intestinal inflammation, dermatological models, ocular studies, neuroinflammation, and antimicrobial investigations demonstrates KPV's versatility as a laboratory tool. Combined with the ongoing advances in nanoparticle and conjugate delivery systems, KPV remains an active and expanding area of peptide research.

---

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

References

1. Luger TA, Scholzen TE, Brzoska T, Böhm M. "α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Ann Rheum Dis. 2007;66 Suppl 3:iii52-5. PubMed

2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178. PubMed

3. Kannengiesser K, Maaser C, Heidemann J, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis. 2008;14(3):324-331. PubMed

4. Cutuli M, Cristiani S, Lipton JM, Catania A. "Antimicrobial effects of alpha-MSH peptides." J Leukoc Biol. 2000;67(2):233-239. PubMed

5. Catania A, Colombo G, Rossi C, et al. "Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]₂." J Pept Res. 2005;66(1):19-26. PubMed

6. Catania A, Rajora N, Capsoni F, Minonzio F, Star RA, Lipton JM. "The neuropeptide alpha-MSH in host defense." Ann N Y Acad Sci. 2000;917:227-231. PubMed

7. Brzoska T, Böhm M, Lügering A, et al. "Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists." Int J Biochem Cell Biol. 2012;4(2):59-73. PubMed

8. Catania A, Garofalo L, Cutuli M, Gringeri A, Santagostino E, Leonardi L. "Effects of the COOH-terminal tripeptide α-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide." Exp Eye Res. 2006;83(6):1366-1372. PubMed

9. Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. "Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model." Gastroenterology. 2010;138(3):843-853. PubMed

10. Xiao B, Xu Z, Viennois E, et al. "Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis." Mol Ther. 2017;25(7):1628-1640. PMC

11. Ichiyama T, Sakai T, Catania A, Barsh GS, Furukawa S, Lipton JM. "The neuroimmunomodulatory peptide alpha-MSH." Ann N Y Acad Sci. 2000;917:221-226. PubMed

12. Galimberti D, Baron P, Meda L, et al. "Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma." Biochem Biophys Res Commun. 1999;263(1):251-256. PubMed

---

Further Reading:

• •CGRP (Calcitonin Gene-Related Peptide): The Vasodilatory Neuropeptide Bridging Pain, Cardiovascular, and Tissue Repair Research
• •PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide): The Pleiotropic Neuropeptide Driving Neuroscience and Stress Research
• •Melanotan II (MT-II): The Cyclic Melanocortin Agonist Reshaping Pigmentation and Receptor Signaling Research
• •Vasoactive Intestinal Peptide (VIP): The Pleiotropic Neuropeptide in Neuroimmune and Circadian Research
• •Reconstitution Calculator
• •Peptide Stack Builder

---

This article is for research and educational purposes only. KPV is a research compound intended for laboratory investigation. All references describe in vitro or in vivo laboratory studies. Always consult applicable regulations before conducting research with peptide compounds.

---

Where to Source KPV for Research: Live Supplier Pricing

KPV (Lys-Pro-Val) is a short α-MSH-derived tripeptide available from 64 active listings in the peptides.so supplier network. Pricing data reflects current in-stock availability (September 2026).

Market range: $0.10–$110/mg across 65 active listings. KPV is relatively affordable per mg given its tripeptide structure. Standard research vials are 5–10mg.

> Compare real-time KPV pricing from all verified suppliers: KPV Supplier Comparison

KPV is also available in combination products with GHK-Cu (the GHK-Cu/KPV blend) for research protocols examining synergistic anti-inflammatory and skin repair pathways. The Beauty Blend (GHK-Cu/KPV) provides 50mg GHK-Cu + 20mg KPV across 56 supplier listings, ranging from $0.50–$375/mg.

---

Frequently Asked Questions

Q: What is KPV and where does it come from?

A: KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Research has shown that this three-amino-acid sequence retains significant anti-inflammatory activity of the parent peptide while being small enough for oral or topical delivery routes in experimental models ([Kanwar et al., 2009]()). It acts via MC1R-dependent and independent pathways to inhibit NF-κB activation.

Q: How does KPV differ from α-MSH?

A: α-MSH is a 13-amino-acid peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) that acts on all five melanocortin receptors (MC1R–MC5R). KPV represents only the C-terminal Lys-Pro-Val tripeptide and binds preferentially to MC1R. Key functional differences: α-MSH has broader hormonal effects including pigmentation and appetite regulation; KPV's primary studied application is anti-inflammatory signaling, particularly in intestinal and skin inflammation models.

Q: What research models have been used to study KPV?

A: KPV has been studied in: (1) murine DSS-induced colitis models, where oral KPV loaded in hydrogel nanoparticles reduced inflammation markers; (2) LPS-stimulated macrophage cultures measuring TNF-α, IL-1β, and IL-6 suppression; (3) skin keratinocyte models examining NF-κB pathway inhibition; (4) in vitro human intestinal epithelial cell models. All published data is preclinical or in vitro.

Q: Can KPV be combined with GHK-Cu in research?

A: GHK-Cu and KPV are frequently combined in experimental protocols because they have complementary mechanisms: GHK-Cu promotes tissue remodeling, collagen synthesis, and wound healing via TGF-β and MMP regulation, while KPV suppresses inflammatory signaling via MC1R/NF-κB. The Beauty Blend (GHK-Cu/KPV) is available from 56 suppliers for research protocols examining synergistic anti-inflammatory and skin repair pathways. See the Peptide Stack Buying Guide for multi-compound purchasing strategies.

Q: Is KPV stable and how should it be stored?

A: KPV's tripeptide structure makes it relatively stable compared to larger peptides. Lyophilized powder is stable at −20°C for years; reconstituted solutions are stable 48–72 hours at 4°C in sterile water or PBS. Its small molecular weight (~340 Da) means it is not prone to aggregation, though avoid repeated freeze-thaw cycles.

Q: What purity should I require for KPV?

A: ≥98% HPLC purity confirmed by mass spectrometry (expected MW: ~340 Da for the free form). Given the tripeptide's small size, synthesis is straightforward and high purity should be standard from any reputable supplier.

---

For research purposes only. KPV is a research chemical for laboratory investigation only. Not for human or animal administration. RUO.